Newsmeme!
Discover News you didn't know existed
Two more cases of the H1N1 virus, also known as swine flu, have been confirmed in the Cochrane District. An 18-year-old Timmins man and a 25-year-old man from Kapuskasing are showing mild flu-like symptoms and are recovering at home.[...]
Plans to replace the reservoir have sparked an uproar among local environmentalists. (photo by Michael Lanza) The skewed results of a public survey presented last Tuesday is leading many Ridgewood Reservoir advocates to ask: is the Parks Department stuffing the ballot box?
Immigration reform was a hot topic during President Barack Obama’s campaign, and at the end of last month, he took a step forward on the issue, meeting with congressional leaders.
Readers weigh in on Chelsea's rheumatoid arthritis duo, Generex's diabetes spray, AMAG's stock dip, and Anadys' prospects.
For more than 100 years, the history and heritage of millions of former slaves sat in a dusty warehouse of federal archives. Thursday, modern technology breathed new life into the history of Virginia’s freedmen.
Last week I was pondering the question, “When does a surfboard become a boat?” and the general interaction of surfers and alternative wave craft riders in the same lineup.
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's proposed development plan for SparVax(TM), PharmAthene's next generation recombinant protective antigen (rPA) anthrax vaccine.
Human Genome Sciences, Inc.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese patients.
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company's Unit Dose Budesonide (UDB) product candidate. The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |